170
Participants
Start Date
July 21, 2022
Primary Completion Date
October 15, 2025
Study Completion Date
December 30, 2025
vudalimab
Monoclonal bispecific antibody
NYU Langone Health, New York
Columbia University Medical Center, New York
University of Pennsylvania Health System, Philadelphia
Medical Oncology Hematology Consultants, PA, Newark
Virginia Oncology Associates, Norfolk
Winship Cancer Institute, Emory University, Atlanta
Moffitt Cancer Center, Tampa
Karmanos Cancer Institute, Detroit
Texas Oncology - Central South, Austin
Rocky Mountain Cancer Centers, Aurora
Arizona Oncology Associates, PC - NAHOA, Prescott
Comprehensive Cancer Centers of Nevada-Southern Hills, Las Vegas
Valkyrie Clinical Trials, Los Angeles
UCLA Medical Center, Los Angeles
UCSD Moores Cancer Center, La Jolla
Kaiser Permanente Medical Group, Riverside
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Collaborators (1)
ICON plc
INDUSTRY
Xencor, Inc.
INDUSTRY